Blood-Based Genetic Signature Offers New Pathway for Parkinson’s Diagnosis

Parkinson’s disease, long recognized primarily for its debilitating effects on the central nervous system, is now increasingly understood through the lens of immune system involvement. Recent groundbreaking research from the Université de Montréal has shed new light on how the immune response plays a critical role in the progression and presentation of this complex neurodegenerative disorder. Pioneering work led by Martine Tétreault, a distinguished associate professor of neuroscience, delves deeply into the peripheral immune landscape of Parkinson’s patients, utilizing state-of-the-art techniques that reveal previously obscured cellular dynamics.

The study employs single-cell RNA sequencing (scRNA-seq), a revolutionary technology that dissects the genetic activity of individual cells rather than bulk tissue. This allows researchers to classify distinct immune cell subtypes circulating in the blood and to capture their unique gene expression profiles with unprecedented precision. Tétreault and her team have identified that specific immune cells in Parkinson’s patients are not only activated but exhibit upregulated expression of genes linked to cellular stress responses. These findings suggest that the peripheral immune system may bear a molecular signature that mirrors, or perhaps even influences, the neurodegenerative processes occurring in the brain.

This molecular signature, comprised of a constellation of overexpressed genes associated with immune activation and stress response pathways, offers a novel biomarker profile for Parkinson’s disease. Such a profile holds the promise of transforming the current diagnostic paradigm, which largely relies on clinical observation and symptom-based criteria. Early and accurate diagnosis remains one of the most pressing challenges in managing Parkinson’s, and the identification of blood-based biomarkers opens the door to minimally invasive testing methods that could detect the disease at much earlier stages than ever before.

Crucially, the study’s findings also pave the way toward better differential diagnosis. Parkinsonian syndromes such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) often present overlapping motor symptoms, making clinical distinction difficult. The unique immune cell gene expression signatures identified in this study provide a molecular fingerprint capable of distinguishing true Parkinson’s disease from its phenotypic mimics, a capability that could significantly improve treatment specificity and patient outcomes.

The research cohort consisted of 14 individuals diagnosed with Parkinson’s disease, 6 patients with related Parkinsonian syndromes, and 10 healthy controls. By comparing these groups, Tétreault’s team could robustly define the genetic signatures associated specifically with Parkinson’s. Importantly, the study confirmed that immune activation was a hallmark of Parkinson’s, while different immune profiles characterized other Parkinsonian disorders. These discoveries underscore the value of peripheral immune biomarkers in clinical contexts and in the stratification of patients for inclusion in clinical trials testing novel therapeutics.

In practical terms, this immune-focused approach may ultimately enable neurologists to monitor disease progression and therapeutic response through simple blood tests, circumventing the need for more intrusive and expensive diagnostic tools such as neuroimaging or cerebrospinal fluid analysis. Furthermore, this paradigm shift highlights immune pathways as potential targets for the development of disease-modifying treatments, broadening the scope beyond traditional dopamine-centered therapies.

Beyond diagnostics, the study advances foundational scientific knowledge by providing an open-source atlas of immune cell subtypes found in both healthy individuals and Parkinson’s patients. This atlas is a valuable resource for the broader scientific community and will facilitate further investigations into the interplay between systemic immunity and neurodegeneration. By mapping the immune landscape at single-cell resolution, the study sets a new benchmark for understanding how peripheral immune cells participate in central nervous system diseases.

The clinical significance of this work is underscored by the growing prevalence of Parkinson’s disease. In Canada alone, nearly 110,000 individuals were living with Parkinson’s in 2024, with projections estimating this number to rise to approximately 150,000 by 2034. As the population ages, such conditions will exert substantial strain on healthcare systems worldwide, heightening the urgency for early diagnosis and novel treatment strategies.

Martine Tétreault’s collaboration with Gaël Moquin-Beaubry, Lovatiana Andriamboavonjy, and Sébastien Audet, who contributed as co-first authors, highlights the multidisciplinary effort required to tackle complex neuroimmune interactions. The study’s publication in the prestigious journal Brain further cements its importance and lays the groundwork for future investigations into immune mechanisms underpinning neurodegenerative disorders.

Funding support from the Courtois Foundation and the Weston Family Foundation, along with technical and clinical expertise from neurologists at the University of Montreal Hospital Research Centre (CRCHUM), was instrumental in the successful completion of this research. The researchers also express gratitude to the patients and their families, whose participation was vital to the study’s insights.

In sum, this research marks a significant advance in Parkinson’s disease biology, linking peripheral immune dysregulation to the disease’s molecular fabric. The ability to pinpoint an immune gene expression signature in blood not only promises enhancements in diagnosis but also offers fresh avenues for therapeutic intervention. By harnessing innovative single-cell sequencing technology, Tétreault and colleagues illuminate a path toward precision medicine approaches in neurodegenerative diseases, potentially transforming patient care in the years ahead.

News Publication Date: 26-May-2025

Web References: http://dx.doi.org/10.1093/brain/awaf066

References: Moquin-Beaudry, G., Andriamboavonjy, L., Audet, S., et al. Mapping the peripheral immune landscape of Parkinson’s disease patients with single-cell sequencing. Brain, 26 May 2025.